UA75868C2 - Pharmaceutical composition comprising combination of tramadol and anticonvulsant drug - Google Patents

Pharmaceutical composition comprising combination of tramadol and anticonvulsant drug Download PDF

Info

Publication number: UA75868C2
Authority: UA; Ukraine
Prior art keywords: tramadol; combination; anticonvulsant; pain; drug
Prior art date: 1999-08-20

Application number

UA2002021306A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Ortho Mcneil Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-20

Filing date

2000-09-08

Publication date

2006-06-15

2000-09-08 Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc

2006-06-15 Publication of UA75868C2 publication Critical patent/UA75868C2/uk

Links

229960004380 tramadol Drugs 0.000 title abstract description 98
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title abstract description 96
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title abstract description 94
239000001961 anticonvulsive agent Substances 0.000 title abstract description 70
239000008194 pharmaceutical composition Substances 0.000 title abstract description 30
239000000463 material Substances 0.000 abstract description 58
239000000203 mixture Substances 0.000 abstract description 57
208000002193 Pain Diseases 0.000 abstract description 43
230000036407 pain Effects 0.000 abstract description 39
230000002195 synergetic effect Effects 0.000 abstract description 28
239000004615 ingredient Substances 0.000 abstract description 8
208000020016 psychiatric disease Diseases 0.000 abstract description 6
208000012902 Nervous system disease Diseases 0.000 abstract description 4
239000013066 combination product Substances 0.000 abstract description 2
229940127555 combination product Drugs 0.000 abstract description 2
230000000144 pharmacologic effect Effects 0.000 abstract 1
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 37
229960004394 topiramate Drugs 0.000 description 37
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 30
239000003814 drug Substances 0.000 description 27
229940079593 drug Drugs 0.000 description 26
230000000694 effects Effects 0.000 description 26
229960003965 antiepileptics Drugs 0.000 description 23
230000001773 anti-convulsant effect Effects 0.000 description 22
238000000034 method Methods 0.000 description 22
PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 17
229960003107 tramadol hydrochloride Drugs 0.000 description 17
229960002870 gabapentin Drugs 0.000 description 15
241000700159 Rattus Species 0.000 description 14
229960001848 lamotrigine Drugs 0.000 description 14
PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 14
229940126601 medicinal product Drugs 0.000 description 9
-1 methoxyphenyl Chemical group 0.000 description 9
241000124008 Mammalia Species 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
230000000996 additive effect Effects 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
210000002683 foot Anatomy 0.000 description 7
208000014674 injury Diseases 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
238000001356 surgical procedure Methods 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 6
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
239000000654 additive Substances 0.000 description 6
230000003502 anti-nociceptive effect Effects 0.000 description 6
239000002585 base Substances 0.000 description 6
239000012153 distilled water Substances 0.000 description 6
230000000926 neurological effect Effects 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000000725 suspension Substances 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
230000036592 analgesia Effects 0.000 description 5
230000000202 analgesic effect Effects 0.000 description 5
229940035676 analgesics Drugs 0.000 description 5
239000000730 antalgic agent Substances 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000012458 free base Substances 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000000014 opioid analgesic Substances 0.000 description 5
229960002036 phenytoin Drugs 0.000 description 5
230000008733 trauma Effects 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
208000004454 Hyperalgesia Diseases 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
229940125681 anticonvulsant agent Drugs 0.000 description 4
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000013499 data model Methods 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
230000003533 narcotic effect Effects 0.000 description 4
208000004296 neuralgia Diseases 0.000 description 4
208000021722 neuropathic pain Diseases 0.000 description 4
208000037974 severe injury Diseases 0.000 description 4
230000009528 severe injury Effects 0.000 description 4
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
208000000094 Chronic Pain Diseases 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
206010053552 allodynia Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000002920 convulsive effect Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229960001680 ibuprofen Drugs 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000002981 neuropathic effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
210000001032 spinal nerve Anatomy 0.000 description 3
239000011885 synergistic combination Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
FRVHJVATKMIOPQ-PAPWGAKMSA-N 17-Methyl-5-alpha-androst-2-en-17-beta-ol Chemical compound C([C@@H]1CC2)C=CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 FRVHJVATKMIOPQ-PAPWGAKMSA-N 0.000 description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
206010010774 Constipation Diseases 0.000 description 2
FWJKNZONDWOGMI-UHFFFAOYSA-N Metharbital Chemical compound CCC1(CC)C(=O)NC(=O)N(C)C1=O FWJKNZONDWOGMI-UHFFFAOYSA-N 0.000 description 2
AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
229940127450 Opioid Agonists Drugs 0.000 description 2
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 description 2
XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 description 2
WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 description 2
241000290158 Scapteriscus vicinus Species 0.000 description 2
HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
229960000623 carbamazepine Drugs 0.000 description 2
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229960001403 clobazam Drugs 0.000 description 2
CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 2
229960003120 clonazepam Drugs 0.000 description 2
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
229960004126 codeine Drugs 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
229940028937 divalproex sodium Drugs 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
229960002767 ethosuximide Drugs 0.000 description 2
HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 2
229960001596 famotidine Drugs 0.000 description 2
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
229960000240 hydrocodone Drugs 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
229960000906 mephenytoin Drugs 0.000 description 2
GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 2
ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 description 2
229960003729 mesuximide Drugs 0.000 description 2
229960001703 methylphenobarbital Drugs 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
229940121367 non-opioid analgesics Drugs 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229940005483 opioid analgesics Drugs 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
229960002085 oxycodone Drugs 0.000 description 2
229960005489 paracetamol Drugs 0.000 description 2
229960003274 paramethadione Drugs 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
229960003396 phenacemide Drugs 0.000 description 2
229960004227 phensuximide Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
208000037821 progressive disease Diseases 0.000 description 2
230000004044 response Effects 0.000 description 2
229940084026 sodium valproate Drugs 0.000 description 2
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
229960002573 sultiame Drugs 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
239000003826 tablet Substances 0.000 description 2
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
206010044652 trigeminal neuralgia Diseases 0.000 description 2
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical compound CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
GYNXTHOOAGYMOK-UHFFFAOYSA-N 2-hydroxybutanediamide Chemical compound NC(=O)CC(O)C(N)=O GYNXTHOOAGYMOK-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
241000936344 Bavia Species 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
235000011293 Brassica napus Nutrition 0.000 description 1
240000008100 Brassica rapa Species 0.000 description 1
235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
241000630665 Hada Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
KQCHEWVHXSAJIA-UHFFFAOYSA-N Isoridentin Natural products C1CC(=C)C(O)CC(O)C(C)=CC2OC(=O)C(=C)C21 KQCHEWVHXSAJIA-UHFFFAOYSA-N 0.000 description 1
241000840267 Moma Species 0.000 description 1
206010061296 Motor dysfunction Diseases 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
UWJUQVWARXYRCG-HIFRSBDPSA-N O-Desmethyltramadol Chemical compound CN(C)C[C@H]1CCCC[C@]1(O)C1=CC=CC(O)=C1 UWJUQVWARXYRCG-HIFRSBDPSA-N 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
206010034912 Phobia Diseases 0.000 description 1
241000232219 Platanista Species 0.000 description 1
206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010038678 Respiratory depression Diseases 0.000 description 1
208000005793 Restless legs syndrome Diseases 0.000 description 1
SVCNNZDUGWLODJ-UHFFFAOYSA-N Riddelline Natural products O1C(=O)C(=CC)CC(=C)C(O)(CO)C(=O)OCC2=CCN3C2C1CC3 SVCNNZDUGWLODJ-UHFFFAOYSA-N 0.000 description 1
KQCHEWVHXSAJIA-RNFGUGDUSA-N Ridentin Chemical compound C1CC(=C)[C@H](O)C[C@H](O)C(/C)=C/[C@H]2OC(=O)C(=C)[C@@H]21 KQCHEWVHXSAJIA-RNFGUGDUSA-N 0.000 description 1
208000026137 Soft tissue injury Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000005400 Synovial Cyst Diseases 0.000 description 1
206010043118 Tardive Dyskinesia Diseases 0.000 description 1
GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
229960000571 acetazolamide Drugs 0.000 description 1
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000003574 anti-allodynic effect Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000005452 bending Methods 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
229960001113 butorphanol Drugs 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
229940064790 dilantin Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
229960003533 ethotoin Drugs 0.000 description 1
SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
229960000693 fosphenytoin Drugs 0.000 description 1
238000007429 general method Methods 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940090044 injection Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
238000002386 leaching Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
229960003390 magnesium sulfate Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000000199 molecular distillation Methods 0.000 description 1
239000003612 morphinomimetic agent Substances 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
229940124637 non-opioid analgesic drug Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
229940124636 opioid drug Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
208000019899 phobic disease Diseases 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960001233 pregabalin Drugs 0.000 description 1
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
210000003497 sciatic nerve Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000035900 sweating Effects 0.000 description 1
239000003760 tallow Substances 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
229960004453 trimethadione Drugs 0.000 description 1
IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA2002021306A 1999-08-20 2000-09-08 Pharmaceutical composition comprising combination of tramadol and anticonvulsant drug UA75868C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15020199P	1999-08-20	1999-08-20
PCT/US2000/021622 WO2001013904A2 (en)	1999-08-20	2000-08-09	Composition comprising a tramadol material and an anticonvulsant drug

Publications (1)

Publication Number	Publication Date
UA75868C2 true UA75868C2 (en)	2006-06-15

Family

ID=22533492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002021306A UA75868C2 (en)	1999-08-20	2000-09-08	Pharmaceutical composition comprising combination of tramadol and anticonvulsant drug

Country Status (31)

Country	Link
US (1)	US6562865B1 (pl)
EP (1)	EP1210118B1 (pl)
JP (1)	JP4977297B2 (pl)
KR (1)	KR100758609B1 (pl)
CN (1)	CN1198651C (pl)
AR (1)	AR032132A1 (pl)
AT (1)	ATE284223T1 (pl)
AU (1)	AU782759B2 (pl)
BG (1)	BG65996B1 (pl)
BR (1)	BRPI0013439B8 (pl)
CA (1)	CA2381797C (pl)
CO (1)	CO5190667A1 (pl)
CR (1)	CR6593A (pl)
CZ (1)	CZ2002524A3 (pl)
DE (1)	DE60016602T2 (pl)
EA (1)	EA006598B1 (pl)
ES (1)	ES2234651T3 (pl)
HU (1)	HUP0203198A3 (pl)
IL (2)	IL148019A0 (pl)
MX (1)	MXPA02001820A (pl)
MY (1)	MY136985A (pl)
NO (1)	NO332342B1 (pl)
NZ (1)	NZ517106A (pl)
PL (1)	PL213323B1 (pl)
PT (1)	PT1210118E (pl)
SK (1)	SK286621B6 (pl)
TR (1)	TR200201067T2 (pl)
TW (1)	TWI259769B (pl)
UA (1)	UA75868C2 (pl)
WO (1)	WO2001013904A2 (pl)
ZA (1)	ZA200201403B (pl)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE122004000032I2 (de)	1991-09-06	2006-02-09	Mcneilab Inc	Zusammensetzung die eine Tramadol-Verbindung und Acetaminophen enth{lt, und ihre Verwendung
US7164034B2 (en)	1999-06-10	2007-01-16	Pfizer Inc.	Alpha2delta ligands for fibromyalgia and other disorders
US6562865B1 (en)	1999-08-20	2003-05-13	Ortho-Mcneil Pharmaceutical, Inc.	Composition comprising a tramadol material and an anticonvulsant drug
DE19940740A1 (de) *	1999-08-31	2001-03-01	Gruenenthal Gmbh	Pharmazeutische Salze
DE10049483A1 (de) *	2000-09-29	2002-05-02	Gruenenthal Gmbh	Substituierte 1-Aminobutan-3-ol-Derivate
JP2005512965A (ja) *	2001-09-24	2005-05-12	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	不穏四肢症候群および定期的四肢運動障害の処置に有用な抗痙攣誘導体
US7790905B2 (en)	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en)	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
EP1478400A1 (en) *	2002-02-26	2004-11-24	Ortho-McNeil Pharmaceutical, Inc.	Therapy for the treatment of migraine comprising anticonvulsant derivatives and antimigraine agents
IL163846A0 (en)	2002-03-01	2005-12-18	Univ South Florida	Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP1364649A1 (en) *	2002-05-23	2003-11-26	Cilag AG	Adduct of topiramate and tramadol hydrochioride and uses thereof
CN100360117C (zh)	2002-06-21	2008-01-09	转化医药公司	具有提高的溶出度的药物组合物
CA2504933C (en)	2002-11-06	2012-10-16	Dana-Farber Cancer Institute, Inc.	Methods and compositions for treating cancer using proteasome inhibitors
AU2003296672A1 (en) *	2002-12-13	2004-07-09	Cilag Ag	Controlled release preparations comprising tramadol and topiramate
US8183290B2 (en)	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
KR101043789B1 (ko) *	2003-03-31	2011-06-27	(주)에이스딕시오	디지털 신호 처리를 이용한 전력 측정기 및 그 전력 측정 방법과 그 방법을 수행하는 프로그램을 기록한 컴퓨터로 읽을 수 있는 기록매체
US20090214426A1 (en) *	2004-05-19	2009-08-27	Laura Corradini	Assay Method
MY147767A (en) *	2004-06-16	2013-01-31	Janssen Pharmaceutica Nv	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) *	2004-06-16	2006-08-23	Janssen Pharmaceutica Nv	Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MX2007002309A (es) *	2004-08-24	2007-10-08	Johnson & Johnson	Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
BRPI0516112A (pt) *	2004-10-15	2008-08-26	Janssen Pharmaceutica Nv	métodos para neuroproteção
WO2006113568A2 (en) *	2005-04-19	2006-10-26	Alza Corporation	Controlled delivery dosage form of tramadol and gabapentin
MX2007014613A (es) *	2005-05-20	2008-04-02	Johnson & Johnson	Procedimiento para la preparacion de derivados de sulfamida.
US20070021500A1 (en) *	2005-07-12	2007-01-25	Twyman Roy E	Methods for neuroprotection
EP2314289A1 (en) *	2005-10-31	2011-04-27	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
MXPA05011735A (es) *	2005-11-01	2007-04-30	Leopoldo Espinosa Abdala	Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
US8937096B2 (en)	2005-12-19	2015-01-20	Janssen Pharmaceutica Nv	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155823A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
AR058389A1 (es)	2005-12-19	2008-01-30	Janssen Pharmaceutica Nv	Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8497298B2 (en)	2005-12-19	2013-07-30	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) *	2005-12-19	2014-05-06	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) *	2005-12-19	2014-04-08	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191461A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191474A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191452A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
US20070191449A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070293476A1 (en) *	2006-05-19	2007-12-20	Smith-Swintosky Virginia L	Co-therapy for the treatment of epilepsy and related disorders
WO2007137167A2 (en) *	2006-05-19	2007-11-29	Janssen Pharmaceutica N.V.	Co-therapy for the treatment of epilepsy
ES2531118T5 (es) *	2006-06-15	2022-06-14	Ucb Pharma Gmbh	Composición farmacéutica que comprende lacosamida y levetiracetamo para uso en el tratamiento de la epilepsia
WO2008027557A2 (en) *	2006-08-31	2008-03-06	Spherics, Inc.	Topiramate compositions and methods of enhancing its bioavailability
JP2010508279A (ja) *	2006-10-27	2010-03-18	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	破壊的行動障害の処置法
MX2009001711A (es)	2006-11-17	2009-05-08	Supernus Pharmaceuticals Inc	Formulaciones de liberacion sostenida de topiramato.
EP2363113B1 (en) *	2006-12-04	2017-08-02	Supernus Pharmaceuticals, Inc.	Enhanced immediate release formulations of topiramate
US20090076128A1 (en) *	2007-09-15	2009-03-19	Protia Llc	Deuterium-enriched topiramate
US8263652B2 (en) *	2007-10-31	2012-09-11	Sk Biopharmaceuticals Co., Ltd.	Stabilized pediatric suspension of carisbamate
US8356315B2 (en) *	2007-12-03	2013-01-15	Koncelik Jr Lawrence J	Setting television default channel
US7872046B2 (en)	2008-01-25	2011-01-18	Xenoport, Inc.	Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
JP5563483B2 (ja) *	2008-01-25	2014-07-30	ゼノポート，インコーポレイティド	アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解
WO2009094577A2 (en)	2008-01-25	2009-07-30	Xenoport, Inc.	Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US20090247616A1 (en) *	2008-03-26	2009-10-01	Smith-Swintosky Virginia L	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) *	2008-03-26	2009-10-01	Abdel-Magid Ahmed F	Process for the preparation of benzo-fused heteroaryl sulfamates
JP2010043063A (ja)	2008-05-09	2010-02-25	Agency For Science Technology & Research	川崎病の診断及び治療
AU2009271362B2 (en)	2008-06-23	2014-03-13	Janssen Pharmaceutica Nv	Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US20100003322A1 (en) *	2008-07-03	2010-01-07	Lai Felix S	Enteric coated hydrophobic matrix formulation
US8815939B2 (en)	2008-07-22	2014-08-26	Janssen Pharmaceutica Nv	Substituted sulfamide derivatives
US20100190752A1 (en)	2008-09-05	2010-07-29	Gruenenthal Gmbh	Pharmaceutical Combination
HUE043278T2 (hu)	2008-09-05	2019-08-28	Gruenenthal Gmbh	3-(3-dimetilamino-1-etil-2-metil-propil)-fenolt és pregabalint vagy gabapentint tartalmazó gyógyszerkombináció
US20110053914A1 (en)	2009-08-28	2011-03-03	Gruenenthal Gmbh	Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic
EP2383255A1 (en)	2010-04-28	2011-11-02	Lacer, S.A.	New compounds, synthesis and use thereof in the treatment of pain
WO2012015027A1 (ja)	2010-07-30	2012-02-02	東レ株式会社	神経障害性疼痛の治療剤又は予防剤
EP2530072A1 (en)	2011-06-03	2012-12-05	Lacer, S.A.	New compounds, synthesis and use thereof in the treatment of pain
US10702485B2 (en)	2011-07-09	2020-07-07	Syntrix Biosystems Inc.	Compositions and methods for overcoming resistance to tramadol
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
DE102013009114A1 (de) *	2013-05-29	2014-12-04	Franz Gerstheimer	Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
KR102789754B1 (ko)	2016-01-06	2025-03-31	론자 리미티드	개선된 생산을 위한 단백질 분해의 억제
US11464756B1 (en)	2017-05-19	2022-10-11	Jerry Darm	Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
RU2020134124A (ru)	2018-03-20	2022-04-20	АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи	СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
WO2020044070A1 (es)	2018-08-30	2020-03-05	Grünenthal GmbH	Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático
US12502371B2 (en)	2019-06-27	2025-12-23	Numan Labo Llc	Drug for treating and preventing dementia
US11977085B1 (en)	2023-09-05	2024-05-07	Elan Ehrlich	Date rape drug detection device and method of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3652589A (en)	1967-07-27	1972-03-28	Gruenenthal Chemie	1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3562589A (en) *	1968-09-09	1971-02-09	Ite Imperial Corp	Electrically resetting undervoltage trip for circuit breakers
US4513006A (en) *	1983-09-26	1985-04-23	Mcneil Lab., Inc.	Anticonvulsant sulfamate derivatives
US4587252A (en) *	1984-12-18	1986-05-06	Brighton Pharmaceutical, Inc.	Hydrocodone/ibuprofen pharmaceutical compositions and method
US4569937A (en) *	1985-02-11	1986-02-11	E. I. Du Pont De Nemours And Company	Analgesic mixture of oxycodone and ibuprofen
ZA926732B (en)	1991-09-06	1994-03-04	Mcneilab Inc	Compositions comprising a tramadol material and any of codeine oxycodone or hydrocodone and their use
DE122004000032I2 (de) *	1991-09-06	2006-02-09	Mcneilab Inc	Zusammensetzung die eine Tramadol-Verbindung und Acetaminophen enth{lt, und ihre Verwendung
US5516803A (en)	1991-10-30	1996-05-14	Mcneilab, Inc.	Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
GB9417532D0 (en)	1994-08-31	1994-10-19	Zeneca Ltd	Aromatic compounds
BR9711151A (pt)	1996-08-14	1999-08-17	Searle & Co	Forma cristalina de 4-¬5-metil-3-fenilsoxazol-4-il¾benzenossulfonamida
EP0942752B1 (en) *	1996-08-23	2005-04-20	Algos Pharmaceutical Corporation	Anticonvulsant containing composition for treating neuropathic pain
US5760007A (en) *	1997-07-16	1998-06-02	Ortho Pharmaceutical Corporation	Anticonvulsant derivatives useful in treating neuropathic pain
AU9021298A (en) *	1997-08-15	1999-03-08	Carolyn Ann Fairbanks	Agmatine as a treatment for neuropathic pain
AU750578B2 (en) *	1997-09-08	2002-07-25	Warner-Lambert Company	Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6562865B1 (en)	1999-08-20	2003-05-13	Ortho-Mcneil Pharmaceutical, Inc.	Composition comprising a tramadol material and an anticonvulsant drug

2000
- 2000-08-09 US US09/634,904 patent/US6562865B1/en not_active Expired - Lifetime
- 2000-08-09 AU AU68958/00A patent/AU782759B2/en not_active Expired
- 2000-08-09 PT PT00957321T patent/PT1210118E/pt unknown
- 2000-08-09 HU HU0203198A patent/HUP0203198A3/hu unknown
- 2000-08-09 AT AT00957321T patent/ATE284223T1/de active
- 2000-08-09 CZ CZ2002524A patent/CZ2002524A3/cs unknown
- 2000-08-09 ES ES00957321T patent/ES2234651T3/es not_active Expired - Lifetime
- 2000-08-09 MX MXPA02001820A patent/MXPA02001820A/es active IP Right Grant
- 2000-08-09 CA CA002381797A patent/CA2381797C/en not_active Expired - Fee Related
- 2000-08-09 JP JP2001518042A patent/JP4977297B2/ja not_active Expired - Lifetime
- 2000-08-09 SK SK226-2002A patent/SK286621B6/sk not_active IP Right Cessation
- 2000-08-09 EA EA200200183A patent/EA006598B1/ru not_active IP Right Cessation
- 2000-08-09 BR BRPI0013439 patent/BRPI0013439B8/pt not_active IP Right Cessation
- 2000-08-09 NZ NZ517106A patent/NZ517106A/en not_active IP Right Cessation
- 2000-08-09 TR TR2002/01067T patent/TR200201067T2/xx unknown
- 2000-08-09 DE DE60016602T patent/DE60016602T2/de not_active Expired - Lifetime
- 2000-08-09 WO PCT/US2000/021622 patent/WO2001013904A2/en not_active Ceased
- 2000-08-09 KR KR1020027002005A patent/KR100758609B1/ko not_active Expired - Lifetime
- 2000-08-09 IL IL14801900A patent/IL148019A0/xx unknown
- 2000-08-09 EP EP00957321A patent/EP1210118B1/en not_active Expired - Lifetime
- 2000-08-09 CN CNB008144990A patent/CN1198651C/zh not_active Expired - Lifetime
- 2000-08-09 PL PL353266A patent/PL213323B1/pl unknown
- 2000-08-18 MY MYPI20003811A patent/MY136985A/en unknown
- 2000-08-18 AR ARP000104303A patent/AR032132A1/es unknown
- 2000-08-18 CO CO00062273A patent/CO5190667A1/es active IP Right Grant
- 2000-09-08 UA UA2002021306A patent/UA75868C2/uk unknown
- 2000-09-18 TW TW089116948A patent/TWI259769B/zh not_active IP Right Cessation
2002
- 2002-02-05 IL IL148019A patent/IL148019A/en active IP Right Grant
- 2002-02-13 NO NO20020728A patent/NO332342B1/no not_active IP Right Cessation
- 2002-02-19 BG BG106420A patent/BG65996B1/bg unknown
- 2002-02-19 ZA ZA200201403A patent/ZA200201403B/en unknown
- 2002-02-20 CR CR6593A patent/CR6593A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1379686A (zh)	2002-11-13
DE60016602T2 (de)	2005-11-03
JP4977297B2 (ja)	2012-07-18
NZ517106A (en)	2005-04-29
CA2381797A1 (en)	2001-03-01
CR6593A (es)	2009-01-16
EA200200183A1 (ru)	2002-08-29
PL213323B1 (pl)	2013-02-28
AR032132A1 (es)	2003-10-29
NO332342B1 (no)	2012-09-03
KR100758609B1 (ko)	2007-09-13
BG106420A (bg)	2002-09-30
EA006598B1 (ru)	2006-02-24
IL148019A (en)	2012-03-29
CO5190667A1 (es)	2002-08-29
TWI259769B (en)	2006-08-11
US6562865B1 (en)	2003-05-13
HUP0203198A2 (hu)	2003-02-28
TR200201067T2 (tr)	2002-09-23
EP1210118B1 (en)	2004-12-08
NO20020728D0 (no)	2002-02-13
CN1198651C (zh)	2005-04-27
DE60016602D1 (de)	2005-01-13
MY136985A (en)	2008-12-31
IL148019A0 (en)	2002-09-12
CA2381797C (en)	2008-04-15
BRPI0013439B1 (pt)	2012-07-24
PL353266A1 (pl)	2003-11-03
KR20020025221A (ko)	2002-04-03
NO20020728L (no)	2002-04-05
EP1210118A2 (en)	2002-06-05
MXPA02001820A (es)	2003-07-14
CZ2002524A3 (cs)	2002-11-13
ES2234651T3 (es)	2005-07-01
ATE284223T1 (de)	2004-12-15
SK286621B6 (sk)	2009-02-05
BRPI0013439A (pt)	2002-04-30
HUP0203198A3 (en)	2005-07-28
SK2262002A3 (en)	2003-02-04
AU6895800A (en)	2001-03-19
AU782759B2 (en)	2005-08-25
JP2003507421A (ja)	2003-02-25
ZA200201403B (en)	2003-07-30
WO2001013904A2 (en)	2001-03-01
BG65996B1 (bg)	2010-09-30
BRPI0013439B8 (pt)	2021-07-06
PT1210118E (pt)	2005-02-28
WO2001013904A3 (en)	2001-06-14

Publication	Publication Date	Title
UA75868C2 (en)	2006-06-15	Pharmaceutical composition comprising combination of tramadol and anticonvulsant drug
DE69400799T2 (de)	1997-03-13	Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
KR101630467B1 (ko)	2016-06-14	진통 내성 억제제
DE3786893T2 (de)	1994-03-03	Piperidinderivat zur Schmerzbehandlung.
DE69420776T2 (de)	2000-05-18	Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
DE2823174A1 (de)	1979-01-25	Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose
WO1999024023A2 (de)	1999-05-20	FORMULIERUNG EINER KOMBINATION AUS OPIOID UND α-ADRENERGEM AGONISTEN UND DEREN VERWENDUNG
DE60030654T2 (de)	2007-04-05	Verwendung von Lasofoxifen
DE2520978C3 (de)	1981-02-19	Dosierungseinheit einer festen, oral zu verabreichenden Arzneiform von wasserlöslichen Xanthin-Derivaten
DE69226487T2 (de)	1999-02-18	Verwendung von Furanonderivaten zur Vorbeugung oder Behandlung von Autoimmunkrankheiten
DE3311922C2 (de)	1994-06-23	Verwendung von substituierten 1,4-Benzochinonen bei der Prophylaxe oder Behandlung von Fibrose
DE60120917T2 (de)	2007-01-25	Kombinationspräparat zur krebstherapie
DE69907220T2 (de)	2004-02-05	Verwendung von substanz p antagonisten zur behandlung des chronischen ermüdungssyndroms und/oder der fibromyalgie
JP3415643B2 (ja)	2003-06-09	筋ジストロフィー症治療薬
JP7144052B2 (ja)	2022-09-29	掻痒性皮膚疾患の予防又は治療薬
JPS5921615A (ja)	1984-02-03	鎮痛剤組成物
WO2002007713A2 (de)	2002-01-31	Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten
DE69922808T2 (de)	2005-12-08	Antivirale Zusammensetzungen enthaltend Yohimbin als therapeutischen Wirkstoff
DE2605243A1 (de)	1976-09-02	Pyrazolessigsaeurehaltiges arzneimittel
KR100318519B1 (ko)	2002-04-06	우라실을 유효성분으로 함유하는 관절염치료제
DE60121142T2 (de)	2007-05-16	Zusammensetzung die paracetamol und niflumic säure enthält
WO1998058640A1 (en)	1998-12-30	Ibuprofen and diphenhydramine analgesics
DE19712398A1 (de)	1998-10-01	Orale Anwendung von (+)-0-Demethyltramadol als Schmerzmittel
AT389999B (de)	1990-02-26	Verfahren zur herstellung analgetischer und antiinflammatorischer mittel
BRPI0617252A2 (pt)	2011-07-19	regime de administração para benzodiazepina 5-2-clorofenil)-1,2-diidro-7-flìor-8-metóxi-3-metil-pira zolo [3,4-b] [1,4]